ArticleFrontiers in medicine2026
Case Report: Blastic plasmacytoid dendritic cell neoplasm mimicking systemic lymphoma: a multidisciplinary diagnostic challenge.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is an aggressive hematologic malignancy originating from plasmacytoid dendritic cell precursors. While classic cases present with prominent cutaneous nodules and lymphadenopathy, predominant generalized lymphadenopathy can obscure the diagnosis, frequently resulting in a misdiagnosis of systemic lymphoma. Case presentation: A 56-year-old male presented with a one-month history of generalized pruritic erythema and multi-regional lymphadenopathy. Initial PET-CT demonstrated systemic lymphadenopathy and splenomegaly with increased metabolic activity, mimicking lymphoma. To establish a definitive diagnosis, integrated biopsies of the skin, bone marrow, and inguinal lymph nodes were performed. Bone marrow cytology revealed that unidentified cells accounted for 7% of the total nucleated cells. Immunohistochemical analysis revealed neoplastic cells positive for CD123, CD4, CD56, TCF4, and TCL1, confirming the diagnosis of BPDCN. The patient achieved complete remission (CR) after two cycles of induction chemotherapy with the DA (daunorubicin and cytarabine) regimen, followed by successful consolidation via allogeneic hematopoietic stem cell transplantation (allo-HSCT). At the 4-month post-transplant follow-up, the patient remains in stable remission with no evidence of disease recurrence. Conclusion: This report details a BPDCN presentation that closely mimics systemic lymphoma. A definitive diagnosis hinges on the integration of multi-site histopathological analysis and comprehensive radiographic findings. Early diagnostic precision is paramount for the timely initiation of intensified therapeutic strategies, such as allo-HSCT, which remain the cornerstone for improving long-term survival in this recalcitrant malignancy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.